Abstract:Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by airflow limitation and changes in airway structures that can lead to chronic bronchitis, small airway diseases, and emphysema. COPD is the 3rd leading cause of death worldwide and despite current research, there are no curative disease treatments for COPD. As the prevalence of COPD is higher in people over 60 years old than in younger age groups, COPD is considered a condition of accelerated lung aging. Natural lung aging is associated with molecular, cellular, and physiological changes that cause alteration in lung structure, in lung function and regeneration, and decreased immune system response that could lead to lung disease like COPD. Mechanisms of accelerated lung aging are complex and composed by increased oxidative stress induced by exposure to cigarette smoke, by chronic inflammatory processes, and increased number of senescent cells within the airways. Cellular senescence is the cessation of cell division after a finite number of proliferation cycles or in response to cell stressors, such as oxidative stress. Senescent cells show activation of the cell cycle regulators p21CIP1 (cyclin-dependent kinase inhibitor-1), p16INK4 (cyclin-dependent kinase inhibitor-2A), and p53 (cellular tumor antigen p53) that lead to cell cycle arrest. Senescent cells exhibit a change in their phenotype and their metabolic activity, along with the production of proinflammatory proteins collectively known as senescence-associated secretory phenotype (SASP). This review aims to describe recent developments in our understanding of aging mechanisms and how the acceleration of lung aging participates in COPD pathophysiology and comorbidities. Understanding and targeting aging mechanisms may result in the development of new therapeutics that could be effective for COPD and also for other age-related diseases.

SIRT1 as a Potential Therapeutic Target for Chronic Obstructive Pulmonary Disease

Roles of sirtuin family members in chronic obstructive pulmonary disease

SIRT1 As a Therapeutic Target in Inflammaging of the Pulmonary Disease

SIRT1: An Intermediator of Key Pathways Regulating Pulmonary Diseases

Sirt1 Protects Against Emphysema Via Foxo3-Mediated Reduction of Premature Senescence in Mice

Sirt1 Protects Against Urban Particulate Matter-Induced Airway Inflammation

The role and regulation of SIRT1 in pulmonary fibrosis

SIRT1 Protects Against Cigarette Smoke-Induced Lung Oxidative Stress Via a FOXO3-dependent Mechanism.

The role of Sirtuin 1 and its activators in age-related lung disease

As a Modulator, Multitasking Roles of SIRT1 in Respiratory Diseases

The Effects of Resveratrol on Inflammation and Oxidative Stress in a Rat Model of Chronic Obstructive Pulmonary Disease

Research progress on Sirtuins (SIRTs) family modulators

SIRT1 Redresses the Imbalance of Tissue Inhibitor of Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Development of Mouse Emphysema and Human COPD.

Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development

Potential Natural Small Molecular Compounds for the Treatment of Chronic Obstructive Pulmonary Disease: An Overview

SIRT1 promotes pulmonary artery endothelial cell proliferation by targeting the Akt signaling pathway

Shelterin Telomere Protection Protein 1 Reduction Causes Telomere Attrition and Cellular Senescence via Sirtuin 1 Deacetylase in Chronic Obstructive Pulmonary Disease

Redox Regulation of SIRT1 in Inflammation and Cellular Senescence.

Novel Role of the SIRT1 in Endocrine and Metabolic Diseases

Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a